ZHAO Dongxin, Ph.D., Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. Zhao was a Principal Scientist in the Oncology R&D research unit at Pfizer Inc., San Diego site, where she worked on identification of novel cancer therapeutic targets. Before joining Pfizer, Dr. ZHAO completed her postdoctoral research in the Department of Bioengineering at University of California, San Diego and carried out her PhD in Cell Biology at Peking University. Her current research focuses on revealing principles of genetic rewiring during cancer development and treatment response. She develops novel approaches for mapping genotype to phenotype associations with unprecedented precision and depth to guide precision targeting of cancer vulnerabilities and designing new therapeutic interventions. 

2004.09 - 2010.01 Ph.D. in Cell Biology, Peking University

2000.09 – 2004.06 B.S. in Biological Sciences, Peking University

Work Experience 

2021.02 – Present Principal Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2017.12 – 2021.01 Principal Scientist, Oncology R&D, Pfizer Inc. 

2014.12 – 2017.12 Postdoctoral Scholar, Department of Bioengineering, University of California, San Diego

2013.12 – 2014.12 Postdoctoral Research Associate, Salk Institute for Biological Studies

1. Development and application of high throughput functional genomics technologies. 

2. Revealing principles of genetic rewiring during cancer development and treatment response for identification of novel cancer therapeutic targets.